Diagnosis, Prognosis, and Mechanisms in Panvascular Disease

NCT07151183 | Recruiting DMC

• 1 other identifier: KY2024-233
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to establish a standardized cohort for panvascular diseases, encompassing biological materials such as DNA samples, along with extensive patient medical records and follow-up information. The design of this database will enable it to serve as a comprehensive resource for future medical research. Upon data collection, researchers will conduct various statistical analyses to enhance our understanding of the factors and mechanisms contributing to various panvascular diseases, including coronary heart disease, myocardial infarction, stroke, and peripheral vascular disease. These statistical analyses will also aid in identifying more effective treatment strategies for these conditions. By amassing a large volume of data from a significant number of patients with panvascular diseases, researchers will be able to perform highly precise analyses of the factors influencing the onset, progression, and treatment of these diseases. The results of these precise analyses can then be utilized to optimize clinical practices for the prevention and treatment of panvascular diseases.

Conditions

Panvascular Diseases; Cardiovascular Diseases

Keywords

Panvascular disease; Cardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

• Number of participants with Cardiovascular mortality, Nonfatal myocardial Infarction, Ischemic stroke, Arteriosclerosis Obliterans

  Cardiovascular mortality, Nonfatal myocardial Infarction, Ischemic stroke, Arteriosclerosis Obliterans

  Up to 5 years from baseline

Secondary Outcomes (3)

• All-cause death

  Up to 5 years from baseline

• Rate of receiving vascular revascularization

  Up to 5 years from baseline

• Readmission rate for vascular reasons

  Up to 5 years from baseline

Interventions

No intervention OTHER

No intervention

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with panvascular diseases

You may qualify if:

• Male or female aged 18 to 80 years old;
• Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
• Voluntary participation in this study and provision of signed informed consent.

You may not qualify if:

• Severe hemodynamic instability;
• Severe cardiac dysfunction (EF \< 30%);
• Severe arrhythmias;
• Severe valvular heart disease;
• Cardiomyopathy caused by non-coronary artery diseases;
• Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.);
• Severe non-cardiovascular diseases;
• Women who are pregnant or breastfeeding;
• Individuals who refuse to provide signed informed consent.

Sponsors & Collaborators

• Jinwei Tian: lead

Study Sites (1)

Harbin Medical University

Harbin, Heilongjiang, 150086, China

RECRUITING

Related Publications (6)

• Azad RK, Shulaev V. Metabolomics technology and bioinformatics for precision medicine. Brief Bioinform. 2019 Nov 27;20(6):1957-1971. doi: 10.1093/bib/bbx170.

  PMID: 29304189 BACKGROUND

• Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9. doi: 10.1038/nrm.2016.25. Epub 2016 Mar 16.

  PMID: 26979502 BACKGROUND

• Aitekenov S, Sultangaziyev A, Abdirova P, Yussupova L, Gaipov A, Utegulov Z, Bukasov R. Raman, Infrared and Brillouin Spectroscopies of Biofluids for Medical Diagnostics and for Detection of Biomarkers. Crit Rev Anal Chem. 2023;53(7):1561-1590. doi: 10.1080/10408347.2022.2036941. Epub 2022 Feb 14.

  PMID: 35157535 RESULT

• Matsuura Y, Kanter JE, Bornfeldt KE. Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):e1-e9. doi: 10.1161/ATVBAHA.118.311999. No abstract available.

  PMID: 30586334 RESULT

• Ozcan C, Deleskog A, Schjerning Olsen AM, Nordahl Christensen H, Lock Hansen M, Hilmar Gislason G. Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):25-35. doi: 10.1093/ehjcvp/pvx009.

  PMID: 28444162 RESULT

• Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 Mar 21;297(11):1197-206. doi: 10.1001/jama.297.11.1197.

  PMID: 17374814 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

DNA, RNA, Plasma, and Serum to be collected. Blood samples will be processed for biochemical assays, DNA, RNA, and multi-omics analyses (including metabolomics, proteomics, and lipidomics). All biospecimens will be stored in a certified biobank at -80 °C for future research.

MeSH Terms

Conditions

Cardiovascular Diseases

Central Study Contacts

Tian J Jinwei Tian, MD, PhD

CONTACT

+86-0451-86605180; tianjinweidr2009@163.com

Wang Y Yan Wang, MD, PhD

CONTACT

+86-13936462066; wangyandr2022@hrbmu.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: August 14, 2025
• First Posted: September 3, 2025
• Study Start: December 1, 2024
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: September 3, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)